APR 22, 2017 01:59 PM PDT

Bacteria-infecting Viruses Inspire Creation of Hybrid Antibodies

WRITTEN BY: Kara Marker

It seems humans share a common enemy with some viruses: bacteria. Viruses invade bacterial cells with generally the same agenda that bacteria have when invading the human body - wipe out host cells and multiply. Borrowing a page from the playbook of bacteria-infecting viruses, called bacteriophages, could help researchers enhance the human immune system to better attack the toughest bacterial species.

Summoned by lysibody molecules, large immune cells called macrophages (red) engulf Staphylococcus aureus bacteria (green).

Bacteriophages have unique molecules that recognize and target specific carbohydrate molecules on the cell surface of bacteria, but the human immune system is ignorant of these molecules. “We have co-opted these molecules, and we've put them to work helping the human immune system fight off microbial pathogens," explained lab head Vincent A. Fischetti.

These viruses then use lysins, dubbed “molecular snippers” by Fischetti and his team, to poke holes in the cell surface of the bacterium after latching on to cell surface carbohydrate molecules. Antibodies produced by the human immune system are similar in structure and practice a similar method, but alas they are unable to identify bacterial carbohydrate molecules.

"Both antibodies and lysins have two discrete components,” explained research associate Assaf Raz. “They both have a part that binds their respective target, but whereas the second component of lysins cuts the bacterial cell wall, in antibodies it coordinates an immune response.”

In their study, researchers replaced the parts of human antibodies where their anti-bacterial approach fell short with the advantages of lysins, a switch made possible thanks to the two components sharing similar structure.

"This made it possible for us to mix and match, combining the viral piece responsible for latching onto a carbohydrate with the part of the antibody that tells immune cells how to respond,” Raz said.

The new “best of both worlds” antibody they created was labeled a lysibody, and the researchers ventured next to test lysibodies in a mice model of methicillin-resistant Staphylococcus aureus, commonly known as MRSA, a bacterial species infamous for being resistant to the harshest antibiotic treatments, earning the name of “superbug.”

The mice studies were successful; the experimental lysibodies identified and targeted carbohydrates on the cell surface of MRSA bacteria as well as other strains of S. aureus and even other types of bacteria.

“Based on our results, it may be possible to use not just lysins, but any molecule with a high affinity toward a target on any pathogen -- be it virus, parasite, or fungus -- to create hybrid antibodies," Fischetti claimed. "This approach could make it possible to develop a new class of immune boosting therapies for infectious diseases."

The present study was published in the journal Proceedings for the National Academy of Sciences.

Source: The Rockefeller University

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
SEP 26, 2018
Videos
SEP 26, 2018
Cancer Immunotherapy
Video illustration about how tumor cells are sensed and destroyed by the immune system and how tumors evolve and detect immune-mediated eliminations, as well as iimmunotherapies associated....
OCT 31, 2018
Drug Discovery
OCT 31, 2018
New Drug Target For a Rare Lymphoma
The promise of immunotherapy in oncology is stronger than ever. Now, an international team of scientists and physicians from the Research Institute of the ...
OCT 31, 2018
Immunology
OCT 31, 2018
Blood Clot Reduction
Vaccine developments to reduce blood clotting in stroke patients...
NOV 20, 2018
Immunology
NOV 20, 2018
Mutations Mutations Which Ones Do We Want?
A team at UCSF makes use of new SLICE tool to generate mutations that reveal specific genetic functions....
JAN 03, 2019
Immunology
JAN 03, 2019
Can the Immune System Restore Youth?
Researchers have identified a target gene that allows for premature aging and inflammation. Target drug therapy allows to the effects of aging to reverse in mice....
JAN 20, 2019
Drug Discovery
JAN 20, 2019
Combination Therapeutic Effective for Leishmaniasis and HIV Patients
In a study published in PLOS Neglected Diseases, a special combination therapy has been proven for efficacy in cases of coinfection with Visceral leishmani...
Loading Comments...